British start-up company Mogrify Ltd (Cambridge, UK) has added US$16m from a Series A round to its US$3.7m seed financing in February 2019. Existing investor Ahren Innovation Capital led the round, with Parkwalk, 24Haymarket, and the University of Bristol Enterprise Fund III participating.
After the departure of Peer Schatz, Thierry Bernard is taking over as interim Chief Executive Officer at QIAGEN while the molecular diagnostics company is looking for a permanent head.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-10-14 07:50:002019-10-14 07:50:00QIAGEN: Temporary CEO
John Dombrosky is taking over the helm of the newly founded Oerth Bio, a targeted protein degradation joint venture launched by Bayer and US biotech Arvinas.
Licencing bluebird bio’s Inc know-how and technology in one-time gene therapies, Novo Nordisk A/S tries to get a foothold in the emerging haemophilia A gene therapy market.
It is a brand-new role at Bournemouth-based Life Sciences company Solentim: Mark Stockdale will join the global leader in cell line development instrumentation as as Amalgamator of Business and Biology.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-10-09 12:50:002019-10-09 12:50:00Solentim: Blending biology and business
https://european-biotechnology.com/wp-content/uploads/2024/04/Evotec4.jpg12522000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-10-09 07:51:482019-10-09 07:51:48Evotec and Celmatix enter strategic partnership
Biom’up SA, specialising in surgical hemostasis, appointed Patrice Ferrand as their new CEO. Ferrand replaces Jan Ohrstrom, who was appointed CEO since May and remains Chairman of the Board.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-10-08 12:50:002019-10-08 12:50:00Patrice Ferrand named new Biom’up CEO
Cell transdifferentiation specialist Mogrify Ltd raises US$16m
Latest NewsBritish start-up company Mogrify Ltd (Cambridge, UK) has added US$16m from a Series A round to its US$3.7m seed financing in February 2019. Existing investor Ahren Innovation Capital led the round, with Parkwalk, 24Haymarket, and the University of Bristol Enterprise Fund III participating.
Patient’s organoids predict response to chemotherapy
Latest NewsA new test based on tumour organoids can predict how patients with advanced colorectal cancer respond to chemotherapy treatment.
QIAGEN: Temporary CEO
AppointmentsAfter the departure of Peer Schatz, Thierry Bernard is taking over as interim Chief Executive Officer at QIAGEN while the molecular diagnostics company is looking for a permanent head.
ADC Therapeutics enters licence option deal with Avacta Group
Latest NewsADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer drug conjugates.
Oerth Bio: Joint venture CEO
AppointmentsJohn Dombrosky is taking over the helm of the newly founded Oerth Bio, a targeted protein degradation joint venture launched by Bayer and US biotech Arvinas.
Novo Nordisk enters haemophilia gene therapy field
Latest NewsLicencing bluebird bio’s Inc know-how and technology in one-time gene therapies, Novo Nordisk A/S tries to get a foothold in the emerging haemophilia A gene therapy market.
Solentim: Blending biology and business
AppointmentsIt is a brand-new role at Bournemouth-based Life Sciences company Solentim: Mark Stockdale will join the global leader in cell line development instrumentation as as Amalgamator of Business and Biology.
Evotec and Celmatix enter strategic partnership
Latest NewsEvotec SE has expanded its drug discovery customer base with US women’s health specialist Celmatix Inc.
Patrice Ferrand named new Biom’up CEO
AppointmentsBiom’up SA, specialising in surgical hemostasis, appointed Patrice Ferrand as their new CEO. Ferrand replaces Jan Ohrstrom, who was appointed CEO since May and remains Chairman of the Board.
Qiagen/Illumina: Earthquake in NGS IVD market
Latest NewsQIAGEN and Illumina join forces in the next-gen sequencing-based IVD testing and companion diagnostics market announcing a 15-year collaboration.